EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Top Cited Papers
- 1 February 2014
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (2), 195-199
- https://doi.org/10.1097/jto.0000000000000069
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009Cancer Research and Treatment, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain MetastasisThe American Journal of Pathology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Genes that mediate breast cancer metastasis to the brainNature, 2009
- A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancerEuropean Journal Of Cancer, 2008
- EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsilEuropean Journal Of Cancer, 2007
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1999